- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01799031
Educational Intervention for Reducing Work Disability in Breast Cancer Survivors
Reducing Work Disability in Breast Cancer Survivors
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. Determine the feasibility and usability of the Work Ability Improvement Through Symptom Management and Ergonomic Strategies (WISE) and empirically evaluate its effect on short-term work ability among breast cancer survivors (BCS).
SECONDARY OBJECTIVES:
I. Explore individual and workplace factors associated with work ability in BCS.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications. Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
ARM II: Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
After completion of study treatment, patients are followed up at 3 and 6 months.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- University of Wisconsin Hospital and Clinics
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosed with breast cancer
- Employed at time of cancer diagnosis (defined as paid employment > 20 hours/week)
- Within six months of completion of active treatment
- Working during treatment or intending to return to work following active treatment
- Computer and internet access
Exclusion Criteria:
- Patients who do not intend to continue/resume working following treatment
- Develop distant metastases or progressive disease
- Prior diagnosis of malignancy at any other site except for in situ carcinomas of the cervix or non-melanomatous skin cancers
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm I (WISE)
Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications.
Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
|
Nebenstudien
Nebenstudien
Andere Namen:
Receive access to the WISE web-based educational intervention
Receive standard of care
Andere Namen:
Receive access to the WISE web-based educational intervention
Andere Namen:
|
|
Aktiver Komparator: Arm II (control)
Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
|
Nebenstudien
Nebenstudien
Andere Namen:
Receive standard of care
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Usability of the WISE website as assessed by responses to a 5-point Likert scale
Zeitfenster: 3 months
|
The primary analysis of the effect of the WISE intervention on work ability will be performed using a Wilcoxon rank sum test.
|
3 months
|
|
Usability of the WISE website as assessed by responses to a 5-point Likert scale
Zeitfenster: 6 months
|
The primary analysis of the effect of the WISE intervention on work ability will be performed using a Wilcoxon rank sum test.
|
6 months
|
|
Work ability, assessed by the Work Limitations Questionnaire (WLQ)
Zeitfenster: Baseline
|
Baseline
|
|
|
Work ability, assessed by the WLQ
Zeitfenster: 3 months
|
3 months
|
|
|
Work ability, assessed by the WLQ
Zeitfenster: 6 months
|
6 months
|
|
|
Individual factors, including symptoms assessed using the Symptom Bother-Revised scale (SB-R) and MD Anderson Symptom Inventory (MDASI), socio-demographic factors, individual disease factors, and treatment factors
Zeitfenster: Baseline
|
Baseline
|
|
|
Individual factors, including symptoms assessed using the SB-R and MDASI, socio-demographic factors, individual disease factors, and treatment factors
Zeitfenster: 3 months
|
3 months
|
|
|
Individual factors, including symptoms assessed using the SB-R and MDASI, socio-demographic factors, individual disease factors, and treatment factors
Zeitfenster: 6 months
|
6 months
|
|
|
Workplace factors, including work history, job characteristics, job control, job support, and level of job stress using the Job Content Questionnaire (JCQ)
Zeitfenster: Baseline
|
Baseline
|
|
|
Workplace factors, including work history, job characteristics, job control, job support, and level of job stress using the JCQ
Zeitfenster: 3 months
|
3 months
|
|
|
Workplace factors, including work history, job characteristics, job control, job support, and level of job stress using the JCQ
Zeitfenster: 6 months
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Feasibility measures, including participation/dropout rates, patient satisfaction, usability/satisfaction with WISE, knowledge/use of self-care symptom management/ergonomic strategies, and use of ergonomic/symptom management strategies, and barriers
Zeitfenster: Up to 6 months
|
Up to 6 months
|
|
Self-car symptom management strategies used (if any), workplace strategies implemented, and barriers to implementation
Zeitfenster: Up to 6 months
|
Up to 6 months
|
|
Individuals self-reported work ability, using the Work Ability Index (WAI)
Zeitfenster: Up to 6 months
|
Up to 6 months
|
|
Employment status
Zeitfenster: Up to 6 months
|
Up to 6 months
|
|
Change in job performance or difficulty performing work tasks
Zeitfenster: Baseline to 6 months
|
Baseline to 6 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Mary Sesto, University of Wisconsin, Madison
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- OS12115
- A536130 (Andere Kennung: UW Madison)
- NCI-2012-03055 (Registrierungskennung: NCI Trial ID)
- 2012-0729 (Andere Kennung: Institutional Review Board)
- SMPH\ORTHOPEDIC&REHAB\PT (Andere Kennung: UW Madison)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Xijing HospitalAktiv, nicht rekrutierendBrustkrebs | Brustkrebs (Triple Negative Breast Cancer (TNBC))China
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
Shanghai Henlius BiotechNoch keine RekrutierungBrustkrebs (Triple Negative Breast Cancer (TNBC))China
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi SankyoRekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
-
Jessica Mezzanotte SharpeRekrutierungNicht-kleinzelligem Lungenkrebs | Klassisches Hodgkin-Lymphom | Plattenepithelkarzinom Mund | Melanom (Hautkrebs) | Brustkrebs (Triple Negative Breast Cancer (TNBC)) | Invasives Mammakarzinom | Nierenzellkarzinom (Nierenkrebs) | MSI-H/dMMR RektumkarzinomVereinigte Staaten
Klinische Studien zur Fragebogenverwaltung
-
Virginia Commonwealth UniversityRigel PharmaceuticalsRekrutierungAkute myeloische LeukämieVereinigte Staaten
-
Centre for Research and Technology HellasRekrutierungMyelodysplastische Syndrome | Chronischer lymphatischer LeukämieItalien
-
Catholic University of the Sacred HeartAbgeschlossenLebensqualität | Chirurgische Wunde | Biopsie-Wunde | Heilung von OperationswundenItalien
-
Daewoong Pharmaceutical Co. LTD.AbgeschlossenGesundKorea, Republik von
-
Daewoong Pharmaceutical Co. LTD.Unbekannt
-
Daewoong Pharmaceutical Co. LTD.AbgeschlossenStudie zur Arzneimittelinteraktion zwischen DWC20155/DWC20156 und DWC20161 bei gesunden FreiwilligenGesundKorea, Republik von
-
Fondazione Poliambulanza Istituto OspedalieroUnbekanntMedikationsfehler und andere Fehler und Probleme bei der Produktverwendung | Unerwünschtes ArzneimittelereignisItalien
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Stanford University und andere MitarbeiterRekrutierungMalaria | Plasmodium Vivax-MalariaPeru
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA); Johns Hopkins University; NYU Langone... und andere MitarbeiterAbgeschlossenSubstanzgebrauchsstörungVereinigte Staaten
-
Nova Scotia Health AuthorityNoch keine Rekrutierung